This systematic review and meta-analysis of 13 RCTs (6,060 patients) asks whether aspirin provides equivalent VTE prophylaxis compared to other anticoagulants after total hip and knee replacement. It examines both clot prevention efficacy (DVT and PE rates) and bleeding safety across multiple comparator agents including LMWH and rivaroxaban.
Selecting VTE prophylaxis after arthroplasty has long involved a tradeoff between bleeding risk, cost, and patient burden. LMWH requires daily injections; warfarin requires blood monitoring; newer oral agents are expensive. Aspirin avoids all three — but its adequacy compared to these agents had not been rigorously synthesized in RCT data until this meta-analysis.
For a routine THR or TKR patient without elevated VTE risk, this paper supports aspirin as a defensible first-line choice. The VTE rates, DVT rates, PE rates, and all major bleeding outcomes are statistically equivalent to LMWH and rivaroxaban.
Know the guideline discrepancy: ACCP endorses aspirin monotherapy after both THR and TKR (Grade 1B). NICE requires 10 days of LMWH before aspirin after THR. A distinction this paper's authors explicitly argue is not supported by the current evidence.
One practical edge: aspirin patients had statistically less bruising and lower-limb edema, which matters for wound surveillance and patient-reported outcomes in the early postoperative period.
This systematic review and meta-analysis of 13 RCTs (6,060 patients) asks whether aspirin provides equivalent VTE prophylaxis compared to other anticoagulants after total hip and knee replacement. It examines both clot prevention efficacy (DVT and PE rates) and bleeding safety across multiple comparator agents including LMWH and rivaroxaban.
Selecting VTE prophylaxis after arthroplasty has long involved a tradeoff between bleeding risk, cost, and patient burden. LMWH requires daily injections; warfarin requires blood monitoring; newer oral agents are expensive. Aspirin avoids all three — but its adequacy compared to these agents had not been rigorously synthesized in RCT data until this meta-analysis.
For a routine THR or TKR patient without elevated VTE risk, this paper supports aspirin as a defensible first-line choice. The VTE rates, DVT rates, PE rates, and all major bleeding outcomes are statistically equivalent to LMWH and rivaroxaban.
Know the guideline discrepancy: ACCP endorses aspirin monotherapy after both THR and TKR (Grade 1B). NICE requires 10 days of LMWH before aspirin after THR. A distinction this paper's authors explicitly argue is not supported by the current evidence.
One practical edge: aspirin patients had statistically less bruising and lower-limb edema, which matters for wound surveillance and patient-reported outcomes in the early postoperative period.